Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.57 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.45 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.45 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.45 |
| ▸ | DPP7 | Q9UHL4 | 9/20 | 0.41 |
| ▸ | DPP8 | Q6V1X1 | 5/20 | 0.41 |
| ▸ | DPP9 | Q86TI2 | 5/20 | 0.41 |
| ▸ | CPB2 | Q96IY4 | 5/20 | 0.41 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 3/20 | 0.40 |
| ▸ | FAP | Q12884 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13301966 | 1.00 | GSR (0.57) | GSRGNAI3GNAO1GNAI1DPP7 | |
| SCHEMBL12825493 | 1.00 | GSR (0.57) | GSRGNAI3GNAO1GNAI1DPP7 | |
| SCHEMBL10533308 | 0.98 | GSR (0.55) | GSRGNAI3GNAO1GNAI1DPP7 | |
| SCHEMBL12680192 | 0.94 | GSR (0.48) | GSRGNAI3GNAO1GNAI1DPP7 | |
| SCHEMBL10532179 | 0.94 | GSR (0.48) | GSRGNAI3GNAO1GNAI1DPP7 | |
| SCHEMBL18159727 | 0.94 | GSR (0.48) | GSRGNAI3GNAO1GNAI1DPP7 | |
| SCHEMBL28257116 | 0.86 | GSR (0.55) | GSRGNAI3GNAO1GNAI1DPP7 | |
| SCHEMBL28257117 | 0.86 | GSR (0.55) | GSRGNAI3GNAO1GNAI1DPP7 | |
| SCHEMBL18159724 | 0.85 | DPP7 (0.40) | GSRDPP7DPP8DPP9DPP4 | |
| SCHEMBL10110827 | 0.85 | DPP7 (0.40) | GSRDPP7DPP8DPP9DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116943-A1 | PROCESSES FOR SYNTHESIZING GLUCAGON-LIKE-PEPTIDE 2 (GLP-2) ANALOGUES | ZEALAND PHARMA AS (DK) | 2026-04-30 | — | — | US | disclosed |
| EP-4453017-A1 | PROCESSES FOR SYNTHESIZING GLUCAGON-LIKE-PEPTIDE 2 (GLP-2) ANALOGUES | Zealand Pharma A/S (DK) | 2024-10-30 | — | — | EP | disclosed |
| WO-2023118416-A1 | PROCESSES FOR SYNTHESIZING GLUCAGON-LIKE-PEPTIDE 2 (GLP-2) ANALOGUES | ZEALAND PHARMA A/S (DK) | 2023-06-29 | — | — | WO | disclosed |
| US-20230174985-A1 | MODIFIED PEPTIDE NUCLEIC ACID COMPOSITIONS | NEUBASE THERAPEUTICS, INC. | 2023-06-08 | — | — | US | disclosed |
| US-20230174985-A1 | MODIFIED PEPTIDE NUCLEIC ACID COMPOSITIONS | NEUBASE THERAPEUTICS, INC. | 2023-06-08 | — | — | US | disclosed |
| US-11541049-B2 | Tetrahydroisoquinoline derivatives, preparation process and use thereof | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2023-01-03 | — | — | US | disclosed |
| US-20220183990-A1 | PEPTIDE-FUNCTIONALIZED BIODEGRADABLE POLYMERS FOR EFFICIENT DELIVERY OF VARIOUS RNAS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-06-16 | — | — | US | disclosed |
| US-20210324012-A1 | MODIFIED PEPTIDE NUCLEIC ACID COMPOSITIONS | NEUBASE THERAPEUTICS, INC. | 2021-10-21 | — | — | US | disclosed |
| US-20210309700-A1 | MODIFIED PEPTIDE NUCLEIC ACID COMPOSITIONS | NEUBASE THERAPEUTICS, INC. | 2021-10-07 | — | — | US | disclosed |
| US-20210309997-A1 | MODIFIED PEPTIDE NUCLEIC ACID COMPOSITIONS | NEUBASE THERAPEUTICS, INC. | 2021-10-07 | — | — | US | disclosed |
| US-9132133-B2 | Nitrogen containing compounds | WOCKHARDT LTD. (IN) | 2015-09-15 | — | — | US | disclosed |
| US-20150174133-A1 | NITROGEN CONTAINING COMPOUNDS | WOCKHARDT LIMITED (IN) | 2015-06-25 | — | — | US | disclosed |
| US-20150141669-A1 | PRODRUG OF FLUORINE-CONTAINING AMINO ACID | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2015-05-21 | — | — | US | disclosed |
| US-8987297-B2 | Nitrogen containing compounds | WOCKHARDT LTD. (IN) | 2015-03-24 | — | — | US | disclosed |
| US-20150005285-A1 | Nitrogen containing compounds | WOCKHARDT LIMITED (IN) | 2015-01-01 | — | — | US | disclosed |
| US-8853197-B1 | Nitrogen containing compounds | WOCKHARDT LTD. (IN) | 2014-10-07 | — | — | US | disclosed |
| US-20140275018-A1 | NITROGEN CONTAINING COMPOUNDS | WOCKHARDT LIMITED (IN) | 2014-09-18 | — | — | US | disclosed |
| US-8822450-B2 | 1,6-diazabicyclo [3,2,1] octan-7-one derivatives and their use in the treatment of bacterial infections | WOCKHARDT LTD. (IN) | 2014-09-02 | — | — | US | disclosed |
| US-20140148431-A1 | 1,6- Diazabicyclo [3,2,1] octan-7-one derivatives and their use in the treatment of bacterial infections | WOCKHARDT LIMITED (IN) | 2014-05-29 | — | — | US | disclosed |
| US-20110172193-A1 | PRO-DRUGS OF (E)-7-(3-(2-AMINO-1-FLUOROETHYLIDENE)PIPERIDIN-1-YL)-1-CYCLOPROPYL-6-FLUORO-8-METHOXY-4-OXO-1,4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID | JANSSEN PHARMACEUTICA NV (BE) | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210309700-A1 | MODIFIED PEPTIDE NUCLEIC ACID COMPOSITIONS | TARDBP, SARNP, SNRPE | GSR 2434/4885GNAI3 2731/4885GNAO1 4403/4885 |
| US-20150174133-A1 | NITROGEN CONTAINING COMPOUNDS | NOS2, NOS1, NCF1 | GSR 423/4885GNAI3 2244/4885GNAO1 1229/4885 |
| US-20150005285-A1 | Nitrogen containing compounds | NOS2, NOS1, NCF1 | GSR 423/4885GNAI3 2244/4885GNAO1 1229/4885 |
| US-20210309997-A1 | MODIFIED PEPTIDE NUCLEIC ACID COMPOSITIONS | TARDBP, SARNP, SNRPE | GSR 2434/4885GNAI3 2731/4885GNAO1 4403/4885 |
| US-20140148431-A1 | 1,6- Diazabicyclo [3,2,1] octan-7-one derivatives and their use in the treatment of bacterial infections | ODC1, AOC1, CASP7 | GSR 1984/4885GNAI3 4116/4885GNAO1 1677/4885 |
| US-20210324012-A1 | MODIFIED PEPTIDE NUCLEIC ACID COMPOSITIONS | TARDBP, SARNP, SNRPE | GSR 2434/4885GNAI3 2731/4885GNAO1 4403/4885 |
| US-20230174985-A1 | MODIFIED PEPTIDE NUCLEIC ACID COMPOSITIONS | TARDBP, SARNP, SNRPE | GSR 2434/4885GNAI3 2731/4885GNAO1 4403/4885 |
| US-20110172193-A1 | PRO-DRUGS OF (E)-7-(3-(2-AMINO-1-FLUOROETHYLIDENE)PIPERIDIN-1-YL)-1-CYCLOPROPYL-6-FLUORO-8-METHOXY-4-OXO-1,4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID | ARFGAP1, ABCC1, FPR1 | GSR 2227/4885GNAI3 1620/4885GNAO1 1776/4885 |
| US-20150141669-A1 | PRODRUG OF FLUORINE-CONTAINING AMINO ACID | SLC1A2, SLC1A1, SLC1A3 | GSR 1086/4885GNAI3 577/4885GNAO1 254/4885 |
| US-20220183990-A1 | PEPTIDE-FUNCTIONALIZED BIODEGRADABLE POLYMERS FOR EFFICIENT DELIVERY OF VARIOUS RNAS | RNASE1, SNRPE, HNRNPAB | GSR 1830/4885GNAI3 4337/4885GNAO1 4795/4885 |
| US-11541049-B2 | Tetrahydroisoquinoline derivatives, preparation process and use thereof | CYP3A4, CYP3A43, CYP11B2 | GSR 3091/4885GNAI3 1425/4885GNAO1 875/4885 |
| US-20260116943-A1 | PROCESSES FOR SYNTHESIZING GLUCAGON-LIKE-PEPTIDE 2 (GLP-2) ANALOGUES | GLP1R, PTMS, GCG | GSR 2603/4885GNAI3 2326/4885GNAO1 1470/4885 |
| US-20140275018-A1 | NITROGEN CONTAINING COMPOUNDS | NOS2, NOS1, NCF1 | GSR 423/4885GNAI3 2244/4885GNAO1 1229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.